New insight into NANOG: A novel therapeutic target for ovarian cancer (OC)

Eur J Pharmacol. 2019 Jun 5:852:51-57. doi: 10.1016/j.ejphar.2019.03.003. Epub 2019 Mar 2.

Abstract

Cancer incidence, metastasis, drug resistance and recurrence are still the critical issues of oncological diseases especially Ovarian cancer (OC). It has been suggested that drug resistance and disease relapse are the main causes for the aggressive nature of OC. There is an immediate need to develop novel strategies to understand the mechanism to overcome chemoresistance. Nanog has been found to regulate stemness like cells inside the cancer cells that are termed as Cancer Stem Cells (CSCs). These cells show high self-renewal capacity with a peculiar potential in tumour initiation, heterogeneity, progression, metastasis, recurrence, radiotherapy and multi drug resistance. Recent studies have demonstrated that Nanog, a key transcription factor for pluripotency, has been playing a major role in chemoresistance. In this review, we address the functions of Nanog in both normal and cancer cells, how Nanog is involved in OC tumorigenesis and chemoresistance. This review also highlights the methods that are used for targeting Nanog as a remedy for treating OC. Thus, through this review, we predict that these concepts will open new avenues of research in ovarian cancer stem cells, and would propose Nanog as a target to improve the outcome of chemotherapy.

Keywords: Cancer Stem Cells (CSCs); Chemotherapy; Nanog; Ovarian cancer (OC).

Publication types

  • Review

MeSH terms

  • Animals
  • Carcinogenesis / drug effects
  • Drug Resistance, Neoplasm / drug effects
  • Female
  • Humans
  • Molecular Targeted Therapy / methods*
  • Nanog Homeobox Protein / metabolism*
  • Ovarian Neoplasms / drug therapy*
  • Ovarian Neoplasms / metabolism
  • Ovarian Neoplasms / pathology

Substances

  • Nanog Homeobox Protein